- Aortic intramural hematoma after thrombolysis in a patient with acute massive pulmonary embolism
-
Kim MS, Kim KS, Jung IS, Park JH, Jeong JO, Choi SW, Seong IW
- KMID: 1780113
- Korean J Intern Med.
- 2013 Sep;28(5):619-621.
- doi: 10.3904/kjim.2013.28.5.619
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
-
Choi JW, Lee JS, Paik WH, Song TJ, Kim JW, Bae WK, Kim KA, Kim JG
- KMID: 2363035
- Clin Mol Hepatol.
- 2016 Mar;22(1):168-171.
- doi: 10.3350/cmh.2016.22.1.168
Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
-
Lee TH, Lee KO, Kim YS, Kim SM, Huh KC, Choi YW, Kang YW
- KMID: 1792063
- Korean J Intern Med.
- 2014 May;29(3):370-374.
- doi: 10.3904/kjim.2014.29.3.370
Various adverse events have been reported during combination therapy with pegylated (PEG)-interferon-alpha and ribavirin, although opportunistic infections, especially cryptococcal meningitis, are very rare. A 61-year-old woman complained of headaches and... -
- CITED
-
- Close
- SHARE
-
- Close
- Highly effective peginterferon alpha-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
-
Yang SY, Lee HW, Lee YJ, Park SJ, Yoo KY, Kim HJ
- KMID: 2164362
- Clin Mol Hepatol.
- 2015 Jun;21(2):125-130.
- doi: 10.3350/cmh.2015.21.2.125
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the... -
- CITED
-
- Close
- SHARE
-
- Close
- Pegylated Interferon-Associated Severe Retinopathy in a Patient with Chronic Hepatitis
-
Kang HY, Shin MC
- KMID: 1364871
- Korean J Ophthalmol.
- 2012 Apr;26(2):147-150.
- doi: 10.3341/kjo.2012.26.2.147
This paper reports a case of pegylated interferon-associated retinopathy in a patient with chronic hepatitis C. A 32-year-old female with chronic hepatitis C undergoing pegylated interferon and ribavirin combination therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent trends in the treatment of chronic hepatitis C
-
Jun DW, Tak WY, Bae SH, Lee YJ
- KMID: 1372647
- Korean J Hepatol.
- 2012 Mar;18(1):22-28.
- doi: 10.3350/kjhep.2012.18.1.22
Pegylated interferon and ribavirin combination therapy is accepted as the standard antiviral treatment for chronic hepatitis C regardless of HCV genotype. This combination therapy achieves higher response rates than previous... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence of and risk factors for thyroid dysfunction during peginterferon alpha and ribavirin treatment in patients with chronic hepatitis C
-
Hwang Y, Kim W, Kwon SY, Yu HM, Kim JH, Choe WH
- KMID: 2381583
- Korean J Intern Med.
- 2015 Nov;30(6):792-800.
- doi: 10.3904/kjim.2015.30.6.792
BACKGROUND/AIMS: Thyroid dysfunction (TD) is more likely to occur in patients with chronic hepatitis C (CHC) and is particularly associated with interferon (IFN) treatment. The purpose of this study was... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin(R) in Patients with Type 1 Gaucher Disease
-
Choi JH, Lee BH, Ko JM, Sohn YB, Lee JS, Kim GH, Heo SH, Park JY, Kim YM, Kim JH, Yoo HW
- KMID: 2164444
- J Korean Med Sci.
- 2015 Apr;30(4):378-384.
- doi: 10.3346/jkms.2015.30.4.378
Gaucher disease is a lysosomal storage disease for which enzyme replacement therapy has proven to be effective. A switch-over clinical trial was performed to evaluate the efficacy and safety of... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
-
Hyun SY, Park SY, Lee SY, Kook H, Paik SH, Jang IJ, Lee KS
- KMID: 2366332
- Yonsei Med J.
- 2015 Jul;56(4):935-943.
- doi: 10.3349/ymj.2015.56.4.935
PURPOSE: Beroctocog alfa is a second generation recombinant factor VIII manufactured by removing the B-domain from factor VIII. This prospective clinical trial was conducted to evaluate the efficacy, safety, and... -
- CITED
-
- Close
- SHARE
-
- Close
